Dr. Elizabeth Cherot talks about advances in opioid alternatives, shares what she’s doing to help her patients and encourages women to speak with their doctor about effective non-opioid options to manage pain after surgery including C-sections.
Ed Sandrick, Director of the Veterans Channel for Humana, shares helpful information for veterans to better understand how a Medicare Advantage plan can help round out the coverage provided by VA benefits, allowing veterans to maximize their health benefits and ensure they have the right health Medicare plan in place come January 1.
Dr. Phyllis Zee, discusses the results of the “How America Sleeps and Wakes” survey conducted by The Harris Poll and sponsored by Eisai Inc., that evaluated the perceptions of insomnia patients and household cohabitants regarding the burden of insomnia and sleep difficulties on having a good day.
Rich Purcell, Senior VP of Research & Drug Development at Generex Biotechnology, discusses the NuGenerex MSO (managed services organization) model, areas of healthcare where strategic improvements can make a significant impact, gaps within traditional MSOs and specialties where new models can work best, and how drug discovery and development can be accelerated with revenue-generating business models.
Berndt Modig, CEO, and Dr. Jochen Knolle, CSO, discuss Pharvaris, a clinical-stage company focused on developing oral therapies for hereditary angioedema (HAE) patients. Hereditary angioedema is a rare and potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people. Current therapies are limited by invasive routes of drug administration (injection or infusion), inconvenient dosing regimens, or undesired side effects.
Returning guest Bill Rancic is joined by his wife Giuliana to discuss Giuliana’s experience with cancer and how Bill’s role as a caregiver served as the impetus for them to partner with Astellas Oncology on the C3 Prize (Changing Cancer Care), an annual competition to identify creative ideas to improve the lives of people touched by cancer. They discuss the winners and how the grants (totaling $200K) and resources (professional TEDMED Coaching) will be used to bring the ideas to life and they talk about their latest projects.
Young MDs getting into the field are expressing more and more interest in their job options, including the role of chief medical informatics officer, according to Benjamin Kanter, MD, CMIO of Vocera. That may be the result of daily stories on clinician burnout, or the exciting digital transformation happening in healthcare. Dr. Kanter joins us today to discuss his journey from practicing physician to CMIO. He often consults with medical students about merging their passions for IT and medical school. Often, such students only hear about traditional physician roles – and never about physicians as administrators, or physicians as tech innovators. Dr. Kanter believes that has to change.
Many forms of power; only one that comes from within-personal power. Kemi will share the benefits of personal power & the positive power this brings.
Forensic pathologist, Dr. Bennet Omalu, the man behind the movie “Concussion” discusses his experience as an International Medical Graduate (IMG). He is joined by returning guest, Dr. William Pinsky, President, and CEO of the Educational Commission for Foreign Medical Graduates (ECFMG®) who will discuss the growing physician shortage and the importance of IMGs to meeting U.S. and global health care needs.
Returning guest Dr. Doug Manion’s current work developing cancer therapeutics has been uniquely informed by his connections to family and friends who have suffered from the disease. While his drug development work began with HIV therapies, the last 10 years of his career have focused on cancer therapies. Dr. Manion joined Kleo Pharmaceuticals in 2017. Kleo is a unique immune-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics. The company’s mission is to create fully synthetic compounds that recruit the immune system to destroy cancer cells, but with significant advantages compared to biologics. Kleo’s small molecule and synthetic peptide compounds function similar to highly complex biologics, yet offer enhanced versatility, improved safety, and efficacy and are faster and cost less to develop. Kleo’s lead compound is expected to commence human studies in 2020.